Hope Sterling: Can I just start with a feeling? Not data, not a company name — just a feeling. Because I keep thinking about what it actually is to be person number eighty-something in a clinical trial, sitting in a chair, and the nurse is not bringing you a pill you'll take every morning for the rest of your life. She's bringing you a nasal spray. And then she's done. That's — I mean, that's the treatment.
Michael C. Vincent: You're already inside the story.
Hope Sterling: Because it's insane! Not insane bad, just — these 193 people had already tried two, three, four, sometimes five antidepressants. That's not someone who gave up quickly. That's someone who kept trying and kept hitting a wall.
Michael C. Vincent: Treatment-resistant depression. That's the clinical term — and the FDA has a specific threshold for it: inadequate response to at least two prior antidepressants. This trial went well beyond that floor for most participants.
Hope Sterling: So they're not the easy cases. They're — like, they are the people the system couldn't reach.
Michael C. Vincent: And what they received was a single intranasal dose of BPL-003 — a synthetic 5-MeO-DMT compound. The results landed in JAMA, and by October 28th, 2026, Medscape and the Financial Times were both carrying the story. Benefits that persisted through an eight-week follow-up.
Hope Sterling: Eight weeks from one dose — that's the part that gets me, like that's the part where I just go... wait, really?
Michael C. Vincent: That is, you see, the part worth sitting with before we pull it apart.
Hope Sterling: Eight weeks is like — okay, that number means nothing until you put a person in it. Like, one-third. One third of everyone who gets a major depression diagnosis never clears two antidepressants and just... stays there?
Michael C. Vincent: One third. That is the current estimate — and the FDA's own threshold for treatment-resistant depression is clearing just two adequate trials. Two. So the floor is already that low, and a third of patients can't clear it.
Hope Sterling: Stop. And there's no — like the Mayo Clinic put out something in January 2026 saying we don't even have clear guidelines for what to do with those people next?
Michael C. Vincent: The Mayo Clinic Depression Center convened a consensus panel — published January 2026 — and the finding that stays with me is the absence of treatment-prioritization guidelines. For a population this size. That is the void BPL-003 is trying to walk into.
Hope Sterling: Okay and now I need you to tell me about the toad. Because you said 5-MeO-DMT and I just — where does a desert toad come into a JAMA paper?
Michael C. Vincent: Now, picture it. The Sonoran Desert toad — the Colorado River toad — secretes 5-MeO-DMT naturally. It is a short-acting tryptamine, and people have been extracting it from those secretions for decades outside any clinical context whatsoever. What Beckley Psytech and atai Life Sciences developed — and what those 193 people actually received — was a fully synthetic formulation. No toad. The compound is mebufotenin benzoate. The two companies have since merged into AtaiBeckley, and that synthetic version is what they're carrying forward.
Hope Sterling: I'm — wait, the JAMA paper is technically descended from toad secretion research and that is just sitting in there quietly — nobody's putting that in the headline?
Michael C. Vincent: Medscape ran it October 28th, 2026, same day the Financial Times did. Neither led with the toad. They led with thirty-eight sites — Australia, Europe, the United States — September 2023 through April 2025. Nearly two years of enrollment across three continents. That is a serious infrastructure for a Phase 2b trial.
Hope Sterling: Okay but — does JAMA publishing something mean we should just trust the result? Like, the journal is impressive, I get it, but is that the thing we're leaning on here?
Michael C. Vincent: JAMA publishing it is a signal, not a verdict. And the thing that actually complicates this result — more than the journal, more than the sample size — is that you cannot blind a psychedelic trial. You receive a nasal spray of 5-MeO-DMT and within minutes something shifts in your perception. You know. The participant knows. And once you know, your reported symptom scores are contaminated by what you expect the drug to do.
Hope Sterling: Wait — so the entire double-blind thing just... doesn't work here?
Michael C. Vincent: Structurally, no. And a September 2026 PubMed review said exactly that — five years of expanding psychedelic psychiatry literature, and trial methodology is still called a fundamental source of uncertainty. The clinical evidence is still labeled weak. Despite the field's popularity.
Hope Sterling: So how much of the result is actually the drug, and how much is just — the story patients are telling themselves about receiving some revolutionary one-dose treatment?
Michael C. Vincent: That is the exact question. And it does not have a clean answer yet. Now — esketamine, Spravato, proved you can get FDA approval for an intranasal antidepressant for treatment-resistant depression. That baseline exists. But Spravato didn't solve the blinding problem either, and it's been on the market since 2019.
Hope Sterling: Okay but then — oh, and this is a conflict of interest — the lead researcher on the BPL-003 trial is Mathieu Seynaeve, and he's affiliated with King's College London, which sounds independent, but he's also affiliated with AtaiBeckley. The company whose drug he is testing.
Michael C. Vincent: It's disclosed. It is not hidden. But disclosed is not the same as resolved — and when your outcome measures rely on patients self-reporting how depressed they feel, and those patients cannot be blinded, and the lead researcher has a stake in the result... those three things stack.
Hope Sterling: Like imagine being that researcher, sitting with data in April 2025 when the trial closes — and you can't publish it for eighteen more months. That gap alone should make us curious about something.
Michael C. Vincent: And that eighteen-month lag is actually the thread that pulls us somewhere darker — because the psychedelic field has a documented history of Phase 2 signals that compress or vanish entirely under Phase 3 scrutiny, and what Compass Pathways' still-unreviewed data adds to that picture is something we need to get to.
Hope Sterling: Okay, darker — because that pattern you're describing, Phase 2 looks incredible, Phase 3 quietly buries it — that's happened before in this exact field?
Michael C. Vincent: It's the template. A 2026 eBioMedicine article — published in a Lancet journal, so peer-reviewed, serious — found that the strongest psilocybin Phase 2b signal approximately doubled depression-score reduction at three weeks versus low-dose control. Doubled. That is a headline number. And then by twelve weeks, benefit was unclear.
Hope Sterling: Wait — unclear by twelve weeks? That's — nine weeks later the signal just... dissolves?
Michael C. Vincent: Not dissolves — becomes statistically murky. Which in drug development is almost the same thing. Now, Compass Pathways announced that COMP005, their Phase 3 psilocybin trial, met its primary endpoint. COMP006 showed durable response at twenty-six weeks. Those are significant claims — but as of August 2026 they are company topline announcements. Not peer-reviewed. Nobody outside Compass has stress-tested that data.
Hope Sterling: So we're supposed to — I mean, is a company announcement the same as nothing? Like, that feels like it should mean something.
Michael C. Vincent: It means something. It does not mean what JAMA means. And that distinction is actually where BPL-003 gains ground — the AtaiBeckley data is published, peer-reviewed, sitting in a journal with a century of credibility. But then comes the detail I cannot move past. Trial closes April 2025. JAMA publishes October 2026. That is eighteen months. Nobody in the research brief explains it.
Hope Sterling: Eighteen months of — what? Like, what do you do with a result for eighteen months?
Michael C. Vincent: Picture a data analyst at AtaiBeckley — April 2025, the last patient completes the trial, results are in hand. Could be manufacturing scale-up. Could be patent filings timed to publication. Could be investor relations. I genuinely do not know. And that not-knowing is itself the signal — because BPL-003 remains investigational, unapproved, Phase 3 confirmation entirely absent. Every clinician or investor reading that JAMA paper should register the gap.
Hope Sterling: So the most peer-reviewed thing in this whole space still has an eighteen-month black box sitting right next to it.
Michael C. Vincent: And that black box is the thing. Because esketamine — Spravato — already proved that you can get a psychedelic nasal spray through the FDA, approved for treatment-resistant depression, and still... not actually reach the people who need it. The reimbursement barriers, the requirement for a specialized clinical setting — those haven't gone away. Academic literature in 2026 is still studying whether patients can actually get to it.
Hope Sterling: And AtaiBeckley controls what happens to BPL-003 if Phase 3 works. But like — controlling the pipeline isn't the same thing as, I don't know, someone who's failed five antidepressants and lives three hours from the nearest specialized center actually getting a dose. That gap is just... it doesn't close automatically.
Michael C. Vincent: No. It doesn't.
Hope Sterling: The 193 people in the trial got a dose. That part happened. Whether the next hundred thousand do — that's the question nobody in the JAMA paper can answer.
Michael C. Vincent: That's the one thing I'd carry out of this. Not the toad, not the eighteen months — just that. The distance between a trial and a treatment.
